74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
MannKind Corp
Open
SectorHealthcare
2.63 -7.39
Overview
Share price change
24h
Min
2.59
Max
2.85
Income | -24M -16M |
|---|---|
Sales | 30M 112M |
P/E Sector Avg | 30.35 66.845 |
EPS | 0.01 |
Profit margin | -14.245 |
Employees | 403 |
EBITDA | -20M -2.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +145.76% upside |
Next Earnings | 7 May 2026 |
|---|
Market Cap | -625M 932M |
|---|---|
Previous open | 10.02 |
Previous close | 2.63 |
News Sentiment
By Acuity
63%
37%
302 / 351 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
MannKind Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
MannKind Corp Forecast
Price Target
By TipRanks
145.76% upside
12 Months Forecast
Average 7.25 USD 145.76%
High 10 USD
Low 3.5 USD
Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.
Sentiment
By Acuity
302 / 351 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Live chat